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Paraoxonase-1 (PON1) is a high density lipoprotein (HDL)-associated enzyme
displaying esterase and lactonase activity. PON1 hydrolyzes the oxons of several
organophosphorous insecticides (e.g. paraoxon, diazoxon and chlorpyrifos-oxon) and
metabolizes lipid peroxides of low density lipoproteins (LDL) and HDL. As such, PON1
plays a relevant role in determining susceptibility of organophosphate toxicity and
cardiovascular disease.
The objective of this study was to determine associations of PON1 status (i.e.
genotype and activity levels) with atherosclerosis (ATH) in individuals from the
Southeastern United States. An additional objective was to determine whether PON1
genotype and/or PON1 activity levels influence the capacity of PON1 to metabolize
chlorpyrifos-oxon (CPO) at a relatively low concentration.
Data indicated increasing PON1 activity assessed by hydrolysis of phenyl acetate
is associated with decreased odds of ATH. Furthermore, neither PON1 genotype nor
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PON1 activity levels influence capacity of PON1 to metabolize CPO at a relatively low
concentration.
Keywords: paraoxonase, atherosclerosis, coronary artery disease, cardiovascular disease,
health disparities, chlorpyrifos-oxon, organophosphates, PON1
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CHAPTER I
INTRODUCTION
In every year since 1900, cardiovascular disease (CVD) accounted for more
deaths than any other major cause of death in the United States (Roger et al. 2011). States
in the South (except for Florida) have higher annual age-adjusted mortality rates from
CVD and stroke than states from other regions of the country. The cause for this disparity
is unknown. Low socioeconomic status, exposure to environmental toxicants, and the
increasing prevalence of hypertension are some theories that have developed to explain
the higher stroke mortality rate in the South (Perry and Roccella 1998). CVD is also more
prevalent in African Americans than in Caucasians (Roger et al. 2011).
Paraoxonase-1 (PON1; EC 3.1.8.1) is a calcium dependent enzyme which
functions as an esterase and lactonase. PON1 is a member of a family of proteins that
also includes PON2 and PON3 (Primo-Parmo et al. 1996). PON1 is synthesized primarily
in the liver and is secreted into the plasma, where it is associated with high density
lipoprotein (HDL) particles (Sorenson et al. 1999). Initially characterized for its ability to
hydrolyze organophosphates (OP), the name, PON1, reflects its ability to hydrolyze
paraoxon, the toxic metabolite of the OP insecticide parathion, which is its first and most
studied substrate (Aldridge 1953a; Mazur 1946).
PON1 performs multiple functions. One physiological function of PON1 is the
prevention of low density lipoprotein (LDL) and HDL oxidation by hydrolyzing lipid
peroxides in the lipoprotein; therefore protecting against the development of
1

atherosclerosis (ATH) (Mackness et al. 1991; Shih et al. 1998). The PON1 Q192R
polymorphism involves an arginine (R) to glutamine (Q) amino acid substitution (Atkins
et al. 1993; Humbert et al. 1993). The relationship, if any, of the PON1 Q192R
polymorphism with the development of ATH is unclear. Initial studies suggested that the
PON1192Q alloform was more efficient at metabolizing lipid peroxides in human
atherosclerotic plaque than the PON1192R alloform (Aviram et al. 2000), and thus was
believed to be more effective at preventing ATH. However, recent research has reported
that the PON1192R alloform binds to HDL with greater affinity than the PON1192Q
alloform and therefore demonstrates increased stability and greater lipolactonase activity
(Gaidukov et al. 2006). Thus the effect of the PON1 Q192R polymorphism in
atherosclerotic (ATH) vascular disease is still unknown (Bhattacharyya et al. 2008).
African Americans are reported to have a higher weighted PON1192R allele
frequency, while Caucasians have a higher weighted PON1192Q allele frequency (Costa et
al. 2003b; Scacchi et al. 2003). The population distribution of the PON1192 functional
genotypes (QQ, QR, RR) can be inferred by plotting the rate of diazoxon hydrolysis
(diazoxonase) by the rate of paraoxon hydrolysis (paraoxonase) (Richter and Furlong
1999). Data on the frequency distribution of the PON1192 genotypes has been reported on
numerous populations, but not specifically the Southern populations. The current
consensus is that the PON1 phenotype (i.e. enzyme activity level) is more important than
genotype in estimating an individual‟s risk of disease with individuals having higher
PON1 enzyme activities being more protected from disease than those with lower
enzyme activities (Mackness et al. 2001).
Another key function of PON1 is its ability to hydrolyze the toxic metabolites of
several OP insecticides (e.g. chlorpyrifos-oxon, diazoxon and paraoxon). The PON1
2

Q192R polymorphism significantly affects the catalytic efficiency of hydrolysis of
specific OP substrates (Costa et al. 2003b; Furlong et al. 2000). Transgenic mouse
models of the human hPON1 Q192R polymorphism have demonstrated that the
PON1192R alloform is significantly more efficient in hydrolyzing chlorpyrifos-oxon, the
toxic metabolite of the OP anticholinesterase insecticide chlorpyrifos, than PON1 192Q
alloform and provides better protection against chlorpyrifos-oxon exposure (Richter et al.
2009). The catalytic efficiency with which PON1 degrades toxic OPs determines the
degree of protection provided by PON1 (Costa et al. 2003b; Furlong et al. 2000). In
addition, higher concentrations of PON1 in the serum provide better protection (Cole et
al. 2010; Jansen et al. 2009). When given the wide range of use of OPs and their high
toxicity, research on the role of PON1 in modulating their toxic effects remains of utmost
importance.
Most epidemiological studies concerned with CVD have not focused on southern
populations where cardiovascular health is the worst, nor have African Americans been
an important proportion of the subjects in these studies. Additionally, little research has
been published regarding the frequency distribution of PON1192 genotypes of southern
populations, which have the worst American health statistics. In this study, PON1 status
was determined for African American and Caucasian male and female Southerners for
whom demographic and clinical information was available. A model was developed to
test the association of PON1 status with ATH while accounting for a core group of
clinical and demographic variables. Also in this study, the hydrolysis of chlorpyrifosoxon was measured at a relatively high concentration (320 µM) and a relatively low
concentration (178 nM) by PON1 in the sera of the study population with a high and a
low activity phenotype towards diazoxon and paraoxon.
3

Subjects were enrolled in the study from the clinical practice of Cardiology
Associates of North Mississippi, LLC, a cardiology group located in Tupelo, Mississippi,
which draws the vast majority of its patients from the 26 counties comprising northeast
Mississippi and northwest Alabama. The research division of this clinic, Cardiology
Associates Research, LLC (CARe), collected a total of 200 serum samples from
Caucasians (60 male, 60 female) and African Americans (40 male, 40 female), ages 45
and older. A 60/40 split was chosen to reflect the racial composition of Mississippi.
Subjects were excluded if they were being evaluated for acute coronary syndrome
(recent myocardial infarction or unstable angina), were known or suspected to be infected
with human immunodeficiency virus or hepatitis B, or did not self-declare as either
Caucasian or African American. Participants underwent the diagnostic tests
recommended by their cardiologist. Study records that identified the subject were kept
confidential as required by Federal Privacy Regulations. The protocol was approved by
both the Institutional Review Board of Mississippi State University and the IRB of North
Mississippi Medical Center; the latter provides oversight for studies performed at CARe.
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CHAPTER II
LITERATURE REVIEW
Introduction to Paraoxonase-1 (PON1)
Paraoxonase-1 (PON1; EC 3.1.8.1) is a calcium dependent enzyme which
functions as an esterase and lactonase. In 1946, Mazur was the first to describe the
enzymatic hydrolysis of organophosphorous (OP) compounds by enzymes in animal
tissues (Mazur 1946). This led to the initial identification of the PON1 enzyme during the
1950s. PON1 was named after its ability to hydrolyze the OP substrate paraoxon, which
is the toxic metabolite of the OP insecticide parathion. Because PON1 can also hydrolyze
aromatic esters, such as phenylacetate (arylesterase; EC 3.1.1.2), the term A-esterase was
coined for the enzyme hydrolyzing both compounds (Aldridge 1953a; Aldridge and
Davison 1953b). Another group, B-esterases (e.g., cholinesterases and
carboxylesterases), is inhibited by OPs in the progressive reaction which is time and
temperature dependent (Aldridge 1953a; Aldridge and Davison 1953b). Studies in the
late 1970s and early 1980s indicated a large variability of PON1 activity among
individuals and that the gene frequency for the low activity varied considerably among
different human populations (Diepgen and Geldmacher-von Mallinckrodt 1986; Playfer
et al. 1976; Eckerson et al. 1983; Mueller et al. 1983), suggesting genetically based
differential susceptibility to OP toxicity. It was not until the 1990s that the molecular
basis of the PON1 activity polymorphisms (Humbert et al. 1993; Adkins et al. 1993) and
its role in the toxicity of OP compounds (Lotti 1991a, b) have been determined. More
5

recently, the molecular structure of a recombinant PON1 protein has also been elucidated
(Harel et al. 2004).
Currently, PON1 has been shown to have multiple functions. One physiological
function of PON1 is the prevention of low density lipoprotein (LDL) and high density
lipoprotein (HDL) oxidation by hydrolyzing lipid peroxides in the lipoprotein; therefore,
it may protect against the development of atherosclerosis (ATH) (Aviram and Rosenblat
2004; Mackness et al. 1991). PON1 also functions to hydrolyze OP anticholinesterases
(e.g. chlorpyrifos-oxon and diazoxon, the active metabolites of two OP insecticides,
chlorpyrifos and diazinon, respectively), as well as nerve agents such as sarin, soman and
VX thereby contributing to protection against the toxicity of OP insecticides and nerve
agents (Davies et al. 1996; Li et al. 2000; Shih et al. 1998). This became of great
importance in the field of toxicology, and investigations were conducted focusing on
protection against organophosphate poisoning and prevention of atherosclerotic
development.
The Paraoxonase Family
PON1 is a member of a family of proteins that also includes PON2 and PON3.
The genes encoding for the various PONs are >60% identical and all three are mapped to
nearby loci on the long arm of chromosome 7 (q21.22) in humans (Primo-Parmo et al.
1996). From a molecular evolutionary standpoint, PON2 appears to be the oldest
member, followed by PON3 and PON1 (Draganov and La Du 2004). At the molecular
level, all of the PON gene family members share the ability to hydrolyze aromatic and
long-chain aliphatic lactones and thus the name PON is in fact a misnomer since PON2
and PON3 lack paraoxonase activity (Draganov et al. 2005). For that reason, the PON
6

gene family is most likely evolutionarily linked to lactonases (Kobayashi et al. 1998). Of
the three members of the PON family, the most studied and hence best known is PON1
(van Himbergen et al. 2006).
The PON gene family is expressed in a variety of human tissues (Primo-Parmo et
al. 1996). In humans, PON1 and PON3 mRNA is synthesized and expressed within the
liver (Reddy et al. 2001), while PON2 is expressed in multiple tissues including the heart,
kidney, liver, lung, and testis (Ng et al. 2005; Ng et al. 2001). In human serum, PON1
activity predominates; however, both PON1 and PON3 are secreted into the blood from
the liver where it is tightly bound to HDL particles (KD ≤1 nM) (Gaidukov et al. 2010;
Deakin et al. 2002). In contrast, the human PON2 protein is not found in HDL, LDL, or
the media of cultured cells, but appears to remain intracellular with its active site
protruding to the outside of the cell (Ng et al. 2001). Human PON1 can be found in a
similar orientation in the liver before it is released by a docking process (i.e., HDL
particles temporarily associate with the cell membrane and remove PON1 from the
membrane) (Deakin et al. 2002; Moren et al. 2008).
The PON1 Polymorphisms
Hasset (Hassett et al. 1991) and Adkins (Adkins et al. 1993) are both credited for
determining the human liver PON1 cDNA sequence and molecular characterization of its
polymorphisms. The cloning of the gene resulted in the identification of over 200 singlenucleotide polymorphisms (SNPs) in different regions of the PON1 gene. An early study
indicated that PON activity in human populations exhibited a polymorphic distribution,
and individuals with high, intermediate, and low PON activity could be identified
(Mueller et al. 1983). The molecular basis of PON activity polymorphisms is a missense
7

mutation in the coding region of PON1 resulting in leucine(L)/methionine(M)
substitution at position 55 and glutamine(Q)/arginine(R) substitution at position 192 (La
Du et al. 1993; Li et al. 1995). PON1192 and PON155 genotypes have been established in
several populations utilizing PCR-based methods. The polymorphism at position 192 has
been the most studied, with a weighted PON1192Q allele frequency of 0.75 for Caucasians
and a weighted PON1192R allele frequency of 0.63 for African Americans (Chen et al.
2003; Scacchi et al. 2003).
In addition to the PON1 Q192R and L55M polymorphisms, sequencing of the
non-coding region of PON1 gene has led to the discovery of 13 additional
polymorphisms, of which 5 have been characterized and show varying degrees of
influence over its expression (Brophy et al. 2001; Leviev and James 2000; Suehiro et al.
2000). The most significant of the promoter region polymorphisms is that at position 108, with -108C allele providing levels of PON1 about twice as high as those seen with
the -108T allele (Brophy et al. 2001). The other polymorphisms have not been
characterized and need more investigation.
The catalytic efficiencies of both PON1 Q192R and L55M polymorphisms have
been investigated for effects on the catalytic efficiencies towards specific substrates. The
PON1 L55M polymorphism does not affect catalytic efficiency, but has been associated
with plasma PON1 protein levels, with PON155M alloform being associated with low
plasma PON1 (Mackness et al. 1998). It is suggested that linkage disequilibrium with the
low efficiency of the -108T allele of the -108 promoter region polymorphism plays a role
(Brophy et al. 2001). Research has implied that the PON155M alloform may be less stable
than PON155L alloform (Leviev et al. 2001; Roest et al. 2007).
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The PON1 Q192R polymorphism significantly affects the catalytic efficiency of
PON1. Early studies indicated that the PON1192R allozyme hydrolyzed paraoxon and
chlorpyrifos-oxon more readily than the PON1192Q (Humbert et al. 1993; Adkins et al.
1993). Current research has indicated that this polymorphism was substrate dependent, as
the PON1192Q alloform was found to hydrolyze diazoxon, sarin, and soman more rapidly
than PON1192R in vitro (Davies et al. 1996). However, it has also been shown that both
PON1 alloforms hydrolyze diazoxon with the same efficiency, under physiological
conditions (Li et al. 2000). PON1192Q allozyme also has a higher efficiency in protecting
against LDL oxidation than the PON1192R allozyme (Mackness et al. 1999).
The Structure of Paraoxonase
Human serum PON1 is a glycoprotein of 354 amino acids and its molecular
weight is 43-47kDa (Furlong et al. 1991). PON is a six-bladed β-propeller with two
calcium ions (i.e. Ca1 and Ca2), 7.4 Å apart, in a central tunnel of the PON propeller
(Harel et al. 2004; Kuo and La Du 1998). The calcium in the central section (Ca1) is
referred to as structural calcium, because its dissociation leads to irreversible denaturation
of the protein (Harel et al. 2004; Kuo and La Du 1998). The second calcium (Ca2) is
assigned as the catalytic calcium, because its removal from PON1 or the addition of a
metal ion chelator (EDTA) results in inactivation of the Ca 2+-dependent PON1 activities
towards paraoxon and phenylacetate, but does not affect its ability to protect LDLcholesterol from oxidation (Kuo and La Du 1998). Although the exact mechanism of
PON1‟s protective activities is unknown, results have illustrated that there are separate
active sites on PON1 for paraoxonase and phenylacetate activities (Aviram 1999; Aviram
et al. 1998b).
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PON1 has three cysteine (Cys) residues at positions Cys42, Cys284, and Cys353.
Cysteine residues at positions Cys42 and Cys353 form a disulfide linkage; however, the
Cys284 residue is free (Kuo and La Du 1998). Cys284 is essential for the enzyme‟s activity
and the ability of PON1 to protect from LDL oxidation. Mutating C 284 to alanine (Ala) or
serine (Ser) in recombinant PON1 mutants decreases its paraoxonase and phenylacetate
activities (Sorenson et al. 1995), and complete inhibition of its ability to protect against
oxidation of LDL (Aviram et al. 1998b).
The active site of PON1 contains a histidine dyad formed by His115 and His134.
His115 acts as a general base to activate a water molecule attacking the carbonyl oxygen
of the substrate, whereas His134 is a proton relay and the calcium is stabilizing the
negatively charged intermediate (Harel et al. 2004; Khersonsky and Tawfik 2006).
PON1 and Cardiovascular Disease
The concept of PON1 binding to HDL cholesterol in human serum led to
hypotheses by Mackness that the enzyme might play a role in lipid metabolism and
protection against the development of ATH (Mackness et al. 1991). ATH is a progressive
disease characterized by the accumulation of lipids and fibrous elements in the large
arteries. Risk factors have been implicated in the development of ATH which included
obesity, hypertension, and dyslipidaemia (i.e. elevated total cholesterol, LDL cholesterol,
triglyceride concentrations, and decreased HDL cholesterol) (McKenney 2003). The
antioxidant activity of HDL cholesterol is largely due to its enzyme PON1, located on it
(Mackness et al. 1991).
The most convincing link between PON1 activity and atherosclerosis comes from
animal studies. In vivo experiments with knockout mice (Shih et al. 1998; Shih et al.
10

2000) provide convincing data for the involvement of PON1 in protection from
atherosclerosis (Mackness et al. 1998). From these studies, PON1 knockout mice
developed ATH when fed an atherogenic diet, and their HDL cholesterol failed to prevent
LDL cholesterol oxidation in cultured artery wall cells, in contrast to wild-type HDL
cholesterol. Conversely, transgenic mice over-expressing PON1 had a significant
decrease in ATH lesion development (Tward et al. 2002).
Although animal studies have shown the inverse relationship between PON1
levels and ATH, PON1‟s antioxidant properties in humans are still being investigated. A
large number of studies have tested the association of Q192R polymorphism and the
development of ATH. The PON1192Q alloform is believed to be more protective of
cardiovascular health than the PON1192R alloform because it has a greater capacity to
metabolize oxidized lipids (Costa et al. 2005). However, another study suggests the
PON1192R alloform binds to HDL cholesterol with better affinity than the PON1 192Q
alloform therefore demonstrating increased stability and greater lipolactonase activity
(Gaidukov et al. 2006). A recent meta-analysis of 43 published studies revealed a weak
association of the Q192R polymorphism with ATH (Wheeler et al. 2004). Any
association of Q192R polymorphism with ATH remains unclear. Conflicting results
could be due to small sample size from different populations, different genotyping
methods, different sampling strategies, and different end points (Roest et al. 2007).
The catalytic efficiency with which PON1 metabolizes oxidized lipids determines
the degree of protection provided by PON1. In addition, higher concentrations of PON1
provide better protection; therefore, when determining adequate risk assessment, it is
important to know PON1 levels and activity. In a given population, plasma PON1
activity can vary up to 40-fold (Eckerson et al. 1983; Mueller et al. 1983; Davies et al.
11

1996; Richter and Furlong 1999), and differences in PON1 protein levels up to 13-fold
are also present within a single PON1192 genotype in adults (Davies et al. 1996). Studies
that examine either plasma PON1 activity levels or PON1 status (i.e. activity levels and
PON1192 genotype) is a much better predictor of disease than PON1192 genotype alone
(Jarvik et al. 2000; Mackness et al. 2001; Graner et al. 2006; Gur et al. 2006). There are
many factors that can influence PON1 activity such as diet, environmental factors,
lifestyle, and disease (Costa et al. 2003a). In epidemiological studies, enzyme activity as
well as genotype needs to be considered when determining associations of PON1 with
disease.
PON1 and the Toxicity of Organophosphate (OP) Insecticides
While the ability of PON1 in hydrolyzing a number of OP substrates in vitro is
well established, in vivo studies of the same OPs have emerged more slowly. Early
experiments demonstrated that by injecting of partially purified PON1 from rabbit serum
to rats would protect them against paraoxon and much better protection against
chlorpyrifos-oxon exposures (Li et al. 1995; Furlong et al. 1991; Main 1956; Costa et al.
1990; Li et al. 1993). These studies indicate that increasing serum levels of PON1 by
injection of exogenous source of PON1 (purified rabbit PON1) decreased the acute
toxicity of specific OPs and that PON1 exerted a protective effect when given after OP
exposure.
Recently, PON1 knockout and transgenic animals generated by Shih et al. (Shih et
al. 1998) have provided important new tools to investigate the role of PON1 in
modulating OP toxicity. In the absence of PON1, PON1 null mice showed a dramatic
increase in sensitivity to chlorpyrifos-oxon and diazoxon (Li et al. 2000) when high doses
12

of chlorpyrifos or diazinon was used. It was also demonstrated that PON1 null mice did
not show an increased sensitivity to paraoxon, in spite of having no paraoxonase activity
in plasma and liver (Li et al. 2000). Experiments began to examine the catalytic
efficiency of human PON1s in an attempt to explain why PON1 protected against some
OP compounds and not others.
PON1 protects against OPs that are hydrolyzed with high catalytic efficiency.
Transgenic mice (mice expressing either human PON1192Q allele or human PON1192R
allele) or administration of exogenous PON1 to PON1 null mice experiments by Li et al.
(Li et al. 2000) and Cole et al. (Cole et al. 2005) demonstrated that diazoxon was
hydrolyzed by both PON1-192 alloforms with equal catalytic efficiency and increasing
PON1 levels by injection of either purified human PON1-192 alloform restored
resistance to diazoxon exposure. They also elucidated that the PON1 192R alloform had
better catalytic efficiency for chlorpyrifos-oxon and paraoxon hydrolysis than the
PON1192Q alloform. Chambers (Chambers et al. 1994) and Pond (Pond et al. 1995)
demonstrated that PON1 does not hydrolyze paraoxon efficiently at low concentrations in
vivo, and that other pathways must be involved (e.g. cytochromes P450,
carboxylesterase).
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CHAPTER III
RELATIONSHIP OF PARAOXONASE-1 (PON1) SERUM ACTIVITY AND
GENOTYPE WITH ATHEROSCLEROSIS IN INDIVIDUALS FROM
THE DEEP SOUTH
The paraoxonase (PON) gene family has been extensively investigated recently.
One member of the PON family, paraoxonase-1 (PON1) has been implicated in a wide
variety of human illnesses including cardiovascular disease (CVD), diabetes mellitus, and
obesity (Abbott et al. 1995; Ferretti et al. 2005; Shih et al. 1998). PON1 performs
multiple functions. In humans, PON1 is mainly expressed in the liver, then transported to
the blood where it is tightly bound to high density lipoprotein (HDL) particles (KD <1
nM) (Gaidukov and Tawfik 2005). One physiological function is the prevention of low
density lipoprotein (LDL) and HDL oxidation by hydrolyzing lipid peroxides in
lipoprotein particles; therefore it may protect against the development of atherosclerosis
(ATH) (Shih et al. 1998; Mackness et al. 1991). PON1 also protects against the acute
toxicity of organophosphorus anticholinesterases including nerve agents and insecticides
through hydrolysis of the compounds or their active metabolites (Aldridge and Davison
1953). In fact, paraoxonase received its name for its ability to hydrolyze paraoxon, the
active metabolite of the insecticide parathion.
Studies using mouse models of ATH (ApoE-/- and LDL-R-/-) have consistently
shown that the over expression of PON1 reduces ATH by reducing oxidative stress,
hydrolyzing lipid peroxides, promoting cholesterol efflux from macrophages, and
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increasing reverse cholesterol transport (Aviram and Rosenblat 2004; Rozenberg et al.
2005; Tward et al. 2002). Conversely, studies have shown that PON1-deficient mice have
increased susceptibility to LDL oxidation, increased measures of macrophage oxidative
stress, and larger atherosclerotic lesions than controls (Rozenberg et al. 2003; Shih et al.
2000).
Differences in PON1 activity have been linked to common polymorphisms in
both coding and promoter regions (Davies et al. 1996; Leviev and James 2000). Two
common polymorphisms in the coding region of PON1 are PON1 L55M and PON1
Q192R. The PON1 Q192R polymorphism has the greater influence on enzyme activity
measured in vitro (Davies et al. 1996; Adkins et al. 1993). This polymorphism involves a
glutamine (Q) to arginine (R) substitution at position 192 (Adkins et al. 1993; Humbert et
al. 1993). Several promoter region polymorphisms have been described with the C-108T
polymorphism influencing expression the most (Leviev and James 2000). The
recognition that PON1 prevents lipid peroxide accumulation and that the PON1 Q192R
polymorphism affects the rate of hydrolysis of several pesticide metabolites led to
investigation of the possible association of the PON1 Q192R polymorphism with
atherosclerosis.
The relationship, if any, of the PON1 Q192R polymorphism with the
development of atherosclerosis is unclear. Early research suggested that the PON1 192Q
alloform was more efficient at metabolizing lipid peroxides in human atherosclerotic
plaques than the PON1192R alloform (Aviram et al. 2000), and thus was believed to be
more effective at preventing ATH. In addition several early studies suggested an
association of the PON1192R allele with atherosclerosis (reviewed by Costa et al. (Costa et
al. 2003)). However, recent research indicated that the PON1192R alloform binds to HDL
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with greater affinity than the PON1192Q alloform and therefore demonstrates increased
stability and greater lipolactonase activity (Gaidukov et al. 2006). Also the prevalence of
ATH was greatest in subjects with the PON1192QQ genotype (Bhattacharyya et al. 2008).
A recent meta-analysis found only a weak association of PON1192R with vascular disease
and pointed out the need for more definitive studies (Wang et al. 2011). Richter and
Furlong (Richter and Furlong 1999) have argued that to accurately assess PON1‟s role in
atherosclerosis that both PON1 genotype and phenotype (i.e. activity level), together
known as the PON1 status, must be determined.
An individual‟s functional PON1192 genotype can be determined using a 2substrate assay to generate a 2-dimensional enzyme activity plot (Richter and Furlong
1999). Without actual genotyping, the plot of the rates of diazoxon hydrolysis in the
presence of 2 M NaCl (diazoxonase; DZOaseNa) vs. paraoxon hydrolysis in the presence
of 2 M NaCl (paraoxonase; POaseNa) separates individuals into 3 functional genotypes,
PON1192QQ, PON1192QR and PON1192RR. PON1 activity determined using PhAc as a
substrate in the absence of NaCl does not distinguish between the PON1192Q and the
PON1192R alloforms and thus serves as a measure of PON1 activity independent of
genotype (Richter et al. 2008).
Numerous epidemiological studies have identified factors that increase the risk of
ATH. Important risk factors include: dyslipidemias (e.g. low HDL cholesterol and high
LDL cholesterol), smoking, diabetes mellitus, and hypertension. States in the Southeast
(except Florida) have higher age-adjusted annual mortality rates from CVD than any
other geographic region in the US (Roger et al. 2011). The cause for this disparity is
unknown. Low socioeconomic status, exposure to environmental toxicants, and the
increasing prevalence of hypertension have been proposed to explain the higher stroke
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mortality rate in the South (Perry and Roccella 1998). African American men and women
have higher age-adjusted mortality rates from CVD than Caucasian men and women
(Roger et al. 2011). Little information is available on the frequency distribution of
PON1192 genotypes of US Southern populations, which have among the worst health
statistics in America. Early studies reported that African Americans have a weighted
PON1192Q allele frequency of 0.37 and a weighted PON1192R allele frequency of 0.63,
while Caucasians have a weighted PON1192Q allele frequency of 0.73 and a weighted
PON1192R allele frequency of 0.27 (Chen et al. 2003). A study from our laboratory (Davis
et al. 2009) showed a similar distribution with African Americans having a higher
PON1192R allele frequency, 0.66, and Caucasians having a higher PON1192Q allele
frequency, 0.77.
In the present study, the PON1192 genotype and the PON1 enzymatic activity
(phenotype) were determined for African American and Caucasian male and female
Southerners for whom demographic and clinical information was available. The
enzymatic activity was assessed with three substrates, paraoxon, diazoxon and PhAc.
Statistically significant associations of clinical characteristics and PON1192 genotype and
phenotype with ATH were determined using logistic regression. A model was developed
to test the association of PON1 status with ATH while accounting for a core group of
clinical and demographic variables.
Materials and methods
Study Population
Subjects were enrolled in the study from the clinical practice of Cardiology
Associates of North Mississippi, LLC, a cardiology group located in Tupelo, Mississippi,
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which draws the vast majority of its patients from the 26 counties comprising northeast
Mississippi and northwest Alabama. The research division of this clinic, Cardiology
Associates Research, LLC (CARe), collected a total of 200 serum samples from
Caucasians (60 male, 60 female) and African Americans (40 male, 40 female), ages 45
and older. A 60/40 split was chosen to reflect the racial composition of Mississippi.
Subjects were excluded if they were being evaluated for acute coronary syndrome
(recent myocardial infarction or unstable angina), were known or suspected to be infected
with human immunodeficiency virus or hepatitis B, or did not self-declare as either
Caucasian or African American. Participants underwent the diagnostic tests
recommended by their cardiologist. Study records that identified the subject were kept
confidential as required by Federal Privacy Regulations. The protocol was approved by
both the Institutional Review Board (IRB) of Mississippi State University and the IRB of
North Mississippi Medical Center; the latter provides oversight for studies performed at
CARe.
After obtaining informed written consent, blood samples were collected when
vascular access was established for clinical testing. Serum was isolated by allowing blood
to clot, then centrifuging at 2500-3000 x g at 4°C for 10 to 20 minutes. The serum was
frozen on dry ice and stored at -70°C until analysis. An aliquot of whole blood anticoagulated with K2EDTA was stored at -70°C for PON1 genotypic analysis.
Age, gender, race, diabetes, history of tobacco use, family history of coronary
artery disease or stroke, presence of hypertension, the use of statins, height, weight, waist
circumference in inches, blood pressure, and pulse were also obtained for each
individual. A fasting lipid panel was obtained on the serum collected. All clinical
information was de-identified before release from the clinic. Subjects were classified as
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having ATH if they had either a history of a clinical event resulting from or a mechanical
revascularization procedure for treating coronary artery disease, cerebrovascular disease,
abdomino-aortic disease, or peripheral vascular disease. Subjects were also considered to
have ATH if they had reversible perfusion defects interpreted as myocardial ischemia on
a nuclear stress test. Subjects who did not meet the criteria for ATH were considered not
to have ATH. All diagnostic tests were interpreted by a CARe physician who had no
knowledge of the results of the PON1 assays.
Statin usage of a subject was designated as „yes‟ if the subject was currently on a
statin drug or designated as „no‟ if the subject was not taking a statin. Smoking status of
an individual was assigned an „ever‟ if the subject was still smoking or had ever smoked
or „never‟ if the subject had never smoked.
Because of the large number of participants on statins, LDL cholesterol levels and
statin usage were used to place subjects into one of two categories. Subjects were
considered normal for LDL cholesterol if their levels were ≤ 160 mg/dL, they did not
meet criteria for pharmacologic treatment (McKenney 2003), and they were not currently
taking a statin. Subjects‟ LDL cholesterol levels were considered elevated if their levels
were >160 mg/dL, they were currently taking a statin, or they met the criteria for
pharmacological treatment of elevated LDL cholesterol (McKenney 2003). Subjects were
considered normal for HDL cholesterol if their levels were ≥ 40 mg/dL and low if their
levels were < 40 mg/dL.
Subjects were considered normal for triglycerides if their levels were <200 mg/dL
and they were not taking a fibrate. Subjects were considered abnormal for triglycerides if
their levels were ≥200 mg/dL or they were taking a fibrate. Subjects who were on statin
therapy and had triglycerides <200 mg/dL were considered indeterminate as it was
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assumed statin therapy was prescribed for elevated LDL cholesterol but would influence
triglyceride levels and prevent an accurate designation of baseline triglyceride status (i.e.
off statin therapy).
Subjects were considered normal for total cholesterol if their levels were <200
mg/dL and they were not taking statins. Subjects were considered abnormal for total
cholesterol if their levels were ≥200 mg/dL. Subjects who were on statin therapy and had
a total cholesterol <200 mg/dL were considered indeterminate as it was assumed statin
therapy was prescribed for elevated LDL cholesterol but would influence total cholesterol
levels and prevent an accurate designation of baseline total cholesterol status (i.e. off
statin therapy).
Chemicals and Samples
Paraoxon was synthesized as described previously (Chambers and Chambers
1990). Diazoxon was purchased from ChemService (West Chester, PA). All other
chemicals were purchased from Sigma Chemical Company (St. Louis, MO).
Paraoxonase and Diazoxonase Assays
Paraoxonase and diazoxonase activities were determined by the hydrolysis of
paraoxon and diazoxon, respectively, as described by Richter and Furlong (Richter and
Furlong 1999) with minor modifications (Davis et al. 2009). The paraoxonase assay was
conducted in the presence of 2 M NaCl (POaseNa) and the absence of NaCl (POase). The
diazoxonase assay was conducted in the presence of 2 M NaCl (DZOaseNa) and the
absence of NaCl (DZOase). Samples were run in triplicate. Data were expressed as units
per liter of serum (U/L) where 1 unit = 1 micromole of paraoxon or diazoxon hydrolyzed
per minute.
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The functional genotype was determined by plotting the DZOaseNa activity
versus the POaseNa activity for each sample (Richter and Furlong 1999).
Arylesterase Assay
Arylesterase activity was determined using PhAc as a substrate. The phenol
released from PhAc hydrolysis was measured spectrophotometrically as described
previously (Davis et al. 2009) and the activity was expressed as U/L where 1 unit = 1
micromole of PhAc hydrolyzed per minute. Samples were run in triplicate.
PON1 Genotyping
Genomic DNA was isolated from whole blood using a Sigma-Aldrich®
GenEluteTM Blood Genomic DNA Kit and concentrated using a Qiagen QIAEX®II Gel
Extraction Kit. Following the method received from the Medical Genetics Department of
the University of Washington (Jane Ranchalis, personal communication), a region
containing the PON1192 codon was amplified by PCR to yield a 99 bp product using the
primer pair F 5' TATTGTTGCTGTGGGACCTGAG 3' and R 5'
TGAAAGACTTAAACT 3'. Each PCR reaction contained ~200 ng of purified human
DNA at ~100 ng/µl, 2 µl of 10X AmpliTaq Gold® 360 PCR Buffer (ABI), 2 µl of 25
mM MgCl2, 0.16 µl 25 mM dNTPs (Promega), 0.2 µl of each primer at 25 µM, 0.2 µl
AmpliTaq Gold polymerase (ABI) at 5U/µl, 1 µl of dimethylsulfoxide and water
sufficient to bring the final volume to 20 µl. Since there is a native Alw I restriction site
at codon 192, 10 µl of the PCR product solution was digested with Alw I (NEB)
overnight and visualized by ethidium bromide staining on a 3% agarose gel next to 10 µl
of undigested product solution. The digestion resulted in 63- and 36-bp fragments for
individuals with the PON1192RR genotype; 99-, 63-, and 36-bp fragments for individuals
21

with the PON1192QR genotype; and a single, non-digested 99-bp fragment for individuals
with the PON1192QQ genotype. Sequence data confirmed the results from the restriction
digest analyses for all 50 of the 200 participants sequenced.
Statistical Analysis and Model Development
A chi-square (χ2) test (PROC FREQ, SAS for Windows 9.1.3, SAS Institute Inc.,
Cary, NC, USA) with Bonferroni correction for multiple comparisons when a significant
χ2 was found (p ≤ 0.05), was used to determine differences among race-gender groups
within PON1 genotypes. One-way analysis of variance was used (PROC GLM, SAS for
Windows 9.1.3) to determine if significant differences among race-gender groups (p ≤
0.05) for PON1 enzymatic activities. If the model indicated significant differences among
groups, mean separation tests were conducted using the Tukey adjustment.
The strength of association, expressed as odds ratios (OR), between the
occurrence of ATH and each of the explanatory variables listed in Table 3 was assessed
by logistic regression (PROC LOGISTIC, SAS for Windows v. 9.1.3). Clinical variables
that were found to be associated with ATH with a p-value ≤ 0.25 were used as candidates
in a multivariable model (Hosmer and Lemeshow 1989). After the model was fit, the
variable with the highest p-value was removed manually and the remaining explanatory
variables reassessed. This process was continued until only clinical variables with p-value
≤ 0.05 remained in the model. This multivariable model was designated the core factor
model. The experimental variables for PON1 activity (i.e. activities for hydrolysis of
paraoxon, diazoxon, and PhAc) were then added individually to the core factor model to
test the association between ATH and the experimental variables for PON1 activity while
accounting for the core clinical variables.
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Results
Characterization of the Study Population
Clinical variables were expressed as mean ± SD for continuous data and ratios for
categorical data for each race-gender group (Table 1). Height and weight were used to
determine body mass index (BMI). The categorical variables LDL group, triglyceride
(trig) group, and TotalChol group were determined using the appropriate values from the
lipid panel and information of statin use as described in detail in the Methods section.
PON1 Genotypes
Separation of the 200 individuals of this study into the three functional PON1 192
genotypes through the 2-dimensional plot of POaseNa vs. DZOaseNa was not as clear as
previously reported (Richter and Furlong 1999; Davis et al. 2009) (Table 4Figure 1a). In
fact, the DZOaseNa vs POaseNa plot alone was unable to unambiguously assign a
functional genotype to a number of individuals. Therefore, the PON1192 genotype was
determined using a restriction fragment length polymorphism assay. Assignment of
genotypes to the data points on the DZOaseNa vs POaseNa plot showed that individuals
with each of the three PON1192 genotypes were located in the expected region of the plot
(Figure 2). A greater portion of Caucasians had the PON1192QQ genotype (p≤ 0.0001) than
did the African Americans, while the reverse was true for the PON1192RR genotype (p≤
0.0001) (Figure 1b, c and Table 2). No significant differences were noted in the
population distribution of the PON1192QR genotype (Table 2).
Differences in Serum Enzyme Activities
Serum enzyme activities were expressed as mean ± SD for each race-gender
group (Table 2). African American females had significantly higher POaseNa activities
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than Caucasian females (p= 0.0005) and Caucasian males (p= 0.0002) but no differences
between the other groups were observed (p> 0.1171). Caucasian females had
significantly higher DZOaseNa activities than African American males (p= 0.0321) but
no differences between the other groups were observed (p> 0.1470). African American
females had significantly higher POase activities than Caucasian females (p= 0.0004) and
Caucasian males (p= 0.0003) but no differences between the other groups were observed
(p> 0.1382). No significant differences (p> 0.1054) were detected with DZOase activity
levels among the race-gender groups. African American females had significantly higher
PhAc activities than Caucasian females (p= 0.0216) and Caucasian males (p= 0.0049) but
no difference between the other groups were observed (p> 0.2898).
Associations of ATH with Clinical and Serum Factors
Statistically significant associations (p≤ 0.05) between the presence of ATH and
each of the clinical and serum factors individually were determined by logistic regression
(Table 3). In our study population, increasing age, gender, smoking status, and
classification in the elevated LDL, the low HDL, and the abnormal triglyceride groups
were all associated with ATH. Classification in the elevated LDL cholesterol group had
the strongest association with ATH of all the explanatory variables. Surprisingly,
increasing body mass index (BMI) was associated with decreased odds of ATH.
Increased levels of PON1 activity (expressed as POaseNa, DZOaseNa, POase, DZOase
or PON1 activity determined by the hydrolysis of PhAc) were associated with decreased
odds of ATH.
Factors that were included in the analysis but did not have statistically significant
associations with ATH included race (p= 0.3264), hypertension (p= 0.0898), diabetes
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(p=0.6778), family history of ATH (p= 0.1242), waist circumference (p=0.8021), total
cholesterol group (p= 0.8427), ratio LDL/HDL (p= 0.3466), and PON1192 genotype
(p=0.9792).
Multivariable Logistic Regression Model
A multivariable logistic regression model was developed that showed the
association of individual clinical and serum factors with the occurrence of ATH (Table
4). Triglyceride and total cholesterol groups were not included as variables in the model
because over half the sample population was indeterminate for the variables due to statin
therapy. Statin usage was not included as a variable in the model because it was used to
define the LDL cholesterol groups. The factors age, gender, smoking status,
hypertension, and LDL cholesterol group remained in the model to constitute the core
model. Age showed a direct association with ATH (OR=1.04, p= 0.0251). Gender was
associated with ATH (OR=3.13, p= 0.0011), with males being more likely than females
to have ATH. Subjects who had a history of smoking (OR=1.98, p= 0.0560) or had
hypertension (OR=2.05, p= 0.0888) were more likely to have ATH. History of smoking
and hypertension were both left in the core model, even though their p-values were
>0.05, because they are well-established risk factors for ATH.
Following construction of the core factor model, the various PON1 activity
measurements were added individually to the model to test the association of PON1
activity and ATH. PON1 activity as measured by PhAc hydrolysis was the only activity
measurement that was significantly associated with ATH (p= 0.0317). The presence of
hydrolysis of PhAc in the model increased the maximum-rescaled generalized r2 value
from 0.35 to 0.37.
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Discussion
PON1 is now known to hydrolyze many substrates including organophosphorus
insecticide metabolites and pharmaceuticals (Aldridge and Davison 1953; Draganov et al.
2005). PON1 has also been found to play an important role in the prevention of ATH by
the metabolism of pro-atherogenic oxidized lipids (Shih et al. 1998). To accurately assess
the association of PON1 with ATH an individual‟s PON1 status (genotype and
phenotype) must be determined. Even though individuals from the Deep South (except
Floridians) have higher age-adjusted mortality rates of CVD than people in other regions
of the United States, little is known about the PON1 status in the Southern population.
In the present study, each individual‟s PON1 status was determined. This analysis
included determination of PON1 activity using the three substrates diazoxon, paraoxon,
and PhAc and determination of each individual‟s PON1192 genotype. A core model
consisting of risk factors known to be associated with ATH including age, gender, history
of smoking, presence of hypertension, and LDL cholesterol group was developed. Family
history was not associated with ATH in our study population possibly because many
subjects were unable to provide enough information to accurately assign their family
history. Diabetes also was not associated with ATH in our study population. The lack of
association of diabetes with ATH may be the result of the over representation of diabetics
in the group of individuals without ATH (35 of 104, more than would be expected in a
random sampling of the population, 12.3 % prevalence of diabetes in MS). Most of the
study subjects had been referred for diagnostic testing for coronary disease and, not
surprisingly, had a much higher prevalence of diabetes than the general population.
Increasing BMI was associated with decreased odds of ATH in our study population. The
reason for this is not known though individuals with ATH may have undergone more
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intensive dietary counseling and been more motivated to follow the dietary
recommendations than individuals without ATH.
The association of the various components of PON1 status with ATH was
determined. Interestingly, all of the PON1 enzymatic measurements had an association
with ATH when assessed individually. However, when assessed in the presence of the
clinical factors comprising the core model, only PON1 activity determined by the
hydrolysis of PhAc was associated with ATH with a p≤ 0.05. The maximum-rescaled
generalized r2 value of the core model was 0.35. The addition of PON1 activity (assessed
by the hydrolysis of PhAc) to the core model resulted in an increase of the maximumrescaled generalized r2 value to 0.37. While this increase is not large, this small increase
is of interest because only 5-10% of the risk of ATH is not accounted for by known risk
factors in studies using very large numbers of patients (Yusuf et al. 2004).
The results of this study must be interpreted with a degree of caution. First, the
study population was not randomly selected but consisted of individuals being treated or
evaluated in a cardiology clinic. This selection bias resulted in an over representation of
diabetes in individuals without ATH in the study population and prevented an adequate
evaluation of diabetes in this study. Second, most patients with ATH in this study had a
previous history of ATH and were already being treated (as evidenced by the extensive
use of statins in the study population) thus allowing for the possible alteration of PON1
enzymatic activities. However, use of statins and fibrates has in general been associated
with an increase in PON1 serum activity measures as (reviewed by Paragh et al. (Paragh
et al. 2008)). If such an increase had occurred in the study population, it would obscure a
sparing effect of PON1 activity on ATH occurrence. The ongoing statin treatment also
resulted in the inability to include triglyceride levels and total cholesterol levels in the
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model. In addition, the only screening test for ATH was cardiac nuclear perfusion
imaging for hemodynamically significant coronary artery disease. This may not have
detected subclinical ATH as sensitively as some other imaging modalities used to
diagnose atherosclerosis (e.g. carotid ultrasound) used in previously published studies
(Jarvik et al. 2003; Jarvik et al. 2000). This would result in individuals with subclinical
coronary artery disease being classified as normal (i.e. no atherosclerosis). Despite these
limitations, this study did demonstrate that increased PON1 activity, as measured by
PhAc hydrolysis, is associated with decreased odds of ATH in this Southern population.
Interestingly, in this population the PON1192 genotype was not significantly associated
with ATH.
Conclusions
This study documents a sparing effect of serum PON1 activity as assessed by the
hydrolysis of PhAc on ATH occurrence adjusted for the effect of age, gender, history of
smoking, hypertension, and elevated LDL-cholesterol. Diabetes, family history of ATH,
total cholesterol levels and triglyceride levels are not well investigated in this model. The
possibility of PON1 activity as an independent risk marker of ATH warrants further
investigation to clarify these issues. This is the first study to document a relationship of
PON1 activity with ATH in a population from the Deep South. In addition, the study has
produced a model that will have utility for characterizing ATH risk factors utilizing
larger data sets in the future.
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Table 1

Characterization of study population by race-gender group.
Variables1

TotalPop

AAF2

AAM2

CF2

CM2

n=200

n=40

n=40

n=60

n=60

63 ± 9

60 ± 11

60 ± 7

65 ± 9

64 ± 9

Smoker (Ever/Never)

113/87

13/27

27/13

31/29

42/18

Diabetes (Yes/No)

70/130

18/22

15/25

19/41

18/42

Hypertension (Yes/No)

154/46

35/5

34/6

44/16

41/19

Age

Units

Years

Height

Inches

67 ± 4

65 ± 3

69 ± 3

65 ± 3

70 ± 3

Weight

pounds

198 ± 44

197 ± 54

201 ± 36

183 ± 43

214 ± 38

BMI

kg/m2

31 ± 6

33 ± 8

30 ± 5

31 ± 7

30 ± 5

HDL

mg/dL

48 ± 16

56 ±13

43 ±12

51 ± 16

40 ± 13

LDL

mg/dL

107 ± 36

123 ± 37

98 ± 30

116 ± 40

95 ± 29

Triglycerides

mg/dL

149 ± 97

119 ± 53

126 ± 113

162 ± 73

171 ± 122

TotalChol

mg/dL

185 ± 45

203 ± 43

165 ± 34

202 ± 48

168 ± 39

Statin Use (Yes/No)

121/79

19/21

29/11

30/30

43/17

HDL group (Low/Normal)

76/120

5/34

18/22

14/44

39/20

LDL group (Elevated/Normal)

156/41

25/14

35/5

43/15

53/7

Trig group

43/63

3/19

5/9

19/20

16/15

69/37

21/9

7/8

29/10

12/10

96/104

10/30

25/15

21/39

40/20

(Abnormal/Normal)3
TotalChol group
(Abnormal/Normal)3
Atherosclerosis (Yes/No)
1

Variables: Age, Height, Weight, Body Mass Index (BMI), Total Cholesterol, HDL
cholesterol, and LDL cholesterol are expressed as means ± SD. Variables: Smoker,
Diabetes, Hypertension, Statin Use, HDL group, LDL group, Trig group, and TotalChol
group were expressed as ratios.
2
AAF=African American Female, AAM=African American Male, CF=Caucasian
Female, and CM=Caucasian Male.
3
Subjects receiving statin therapy were not included in the summary statistics for these
variables.
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Table 2
Variables

Serum PON1 parameters of Caucasian and African American males and
females.
Units

TotalPop

AAF

AAM

CF

CM

n = 200

n = 40

n = 40

n = 60

n = 60

POaseNa1

U/L

401 ± 188

509 ± 183A

421 ± 189AB

363 ± 173B

354 ± 178B

DZOaseNa1

U/L

8460 ± 2757

8649 ± 2566AB

7699 ± 2231B

9191 ± 3110A

8130 ± 2741AB

POase1

U/L

98 ± 54

129 ± 56A

104 ± 53AB

85 ± 50B

85 ± 50B

DZOase1

U/L

6437 ± 2249

6141 ± 1814A

6033 ± 1858A

7052 ± 2472A

6300 ± 2445A

PhAc1

U/L

15404 ± 3351

16919 ± 3165A

15685 ± 3542AB

14984 ± 3386B

14656 ± 3041B

QQ

68

5A

9A

29B

25B

QR

87

17A

18A

25A

27A

RR

40

16A

13A

5B

6B

Genotype2

1

Activities of POaseNa, DZOaseNa, POase, DZOase, and hydrolysis of PhAc are
expressed as micromoles substrate hydrolyzed per minute per liter of serum (U/L), means
± SD.
2
Number of individuals in each race-gender group with the indicated genotype.
A, B
Values within a row with the same superscript letter are not significantly different (p≤
0.05) as determined by analysis of variance with Tukey adjustment or by analysis of chisquare (χ2) with Bonferroni adjustment.
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Table 3
Factor1

Odds ratios of atherosclerosis associated with clinical and serum factors.
Comparison

Age

Units

n

Odds Ratio

95% CI

P-Value

5 years

200

1.22

(1.04,1.43)

0.0138

Gender

Male vs Female

200

4.13

(2.29,7.46)

<0.0001

Smoker

Ever vs Never

200

2.45

(1.38,4.31)

0.0023

LDLGroup

Elevated vs Normal

197

10.08

(3.75,27.08)

<0.0001

HDLGroup

Low vs Normal

196

2.66

(1.47,4.82)

0.0012

Triglyceride

Abnormal vs Normal

97

6.57

(2.70,15.97)

0.0267

BMI

5 kg/m2

198

0.75

(0.59,0.95)

0.018

POaseNa2

150 U/L

199

0.78

(0.62,0.98)

0.0326

DZOaseNa2

1000 U/L

199

0.89

(0.80,0.99)

0.0346

15 U/L

199

0.92

(0.85,0.99)

0.0334

DZOase2

1000 U/L

199

0.85

(0.75,0.97)

0.0169

PhAc2

1000 U/L

199

0.89

(0.82,0.98)

0.0128

POase2

1

Factors that were included in study but not found significant at p≤ 0.05 included race,
hypertension, diabetes, family history, waist circumference, total cholesterol group,
LDL/HDL ratio, genotype, DZOaseNa/POaseNa ratios, and DZOase/POase ratios
2
Activities of POaseNa, DZOaseNa, POase, DZOase, and hydrolysis of PhAc are
expressed as micromoles substrate hydrolyzed per minute per liter of serum (U/L), means
± SD.
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Table 4

Multivariable logistic regression model of clinical and serum factors
associated with atherosclerosis occurrence

Factor

Comparison

Age

Units

Odds Ratio

95% CI

P-Value

5 years

1.04

(1.01,1.08)

0.0251

Gender

Male vs. Female

3.13

(1.58,6.23)

0.0011

Smoker1

Ever vs. Never

1.98

(0.98,3.99)

0.0560

Hypertension1

Yes vs. No

2.05

(0.90,4.70)

0.0888

LDLGroup

High vs. Normal

9.56

(3.17, 28.79)

<0.0001

0.89

(0.80,0.99)

0.0317

PhAc

1000 U/L

1

Although the p-values for the association of smoking status and hypertension were
greater than 0.05, the variables were retained in the model because each is an established
risk factor for atherosclerosis
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Figure 1

Plot of serum DZOaseNa vs. POaseNa enzymatic activities.

The sample population (n=200) consisted of 120 Caucasians (60 male, 60 female) and 80
African Americans (40 male, 40 female). (A) Plot of DZOaseNa activities vs. POaseNa
activities in the sera of male and female African American and Caucasian Southerners.
(B) Plot of DZOaseNa activities vs. POaseNa activities in the sera of male and female
Caucasian Southerners. (C) Plot of DZOaseNa activities vs. POaseNa activities in the
sera of male and female African American Southerners
Abbreviations: AAF, African American Female (●); AAM, African American Male (■);
CF, Caucasian Female (○); CM, Caucasian Male (□)
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Figure 2

Plot of DZOaseNa vs. POaseNa enzymatic activities in the sera of male and
female African American and Caucasian Southerners.

Genotypes are PON1192QQ (○); PON1192QR (■); and PON1192RR (Δ). The sample
population (n=200) consisted of 120 Caucasians (60 male, 60 female) and 80 African
Americans (40 male, 40 female)
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CHAPTER IV
PARAOXONASE-1 (PON1) STATUS AND HYDROLYSIS OF CHLORPYRIFOSOXON AT HIGH AND LOW CONCENTRATIONS
Since the removal of organochlorine insecticides (e.g. DDT) from use in the
United States in the 1970‟s, organophosphorous (OP) insecticides have become the most
widely used insecticides available today. With the increasing demand of insecticide
products, as well as insecticide-contaminated food and different formulas, the question of
their safety has become a serious world public health issue. Chlorpyrifos has been used
globally as an insecticide to control crop pests in agriculture, specifically on corn. Over
the past 40 years, research has focused on assessing human exposure to chlorpyrifos (rat
oral LD50, 122-163 mg/kg; (Gaines 1969; McCollister et al. 1974). Our lab has developed
an interest in chlorpyrifos-oxon (CPO), the active metabolite of the phosphorothionate
insecticide chlorpyrifos. This cytochrome P450-generated metabolite exerts acute toxicity
by persistent inhibition of acetylcholinesterase (AChE; E.C. 3.1.1.7) in the peripheral and
central cholinergic nervous systems causing cholinergic overstimulation (Aldridge and
Davison 1953b).
Paraoxonase-1 (PON1; E.C. 3.1.8.1) is synthesized in the liver and circulates in
the plasma associated with both apolipoprotein A1 and high density lipoproteins
(Gaidukov and Tawfik 2005). PON1 protects against the acute toxic effects of OP
anticholinesterases including nerve agents and OP insecticides through hydrolysis of the
compounds or their active metabolite (i.e. the oxons of some OP insecticides) (Aldridge
35

and Davison 1953b). In fact, paraoxonase takes its name from its capability to hydrolyze
paraoxon, the active metabolite of the OP insecticide parathion.
The involvement of PON1 in the in vivo detoxication of CPO and diazoxon, the
active metabolite of the OP insecticide diazinon, has been demonstrated with transgenic
animals. Although mice with a deleted PON1 gene are more susceptible to the toxic
effect of CPO and diazoxon than wild-type mice, surprisingly they are not more
susceptible to paraoxon than wild-type animals (Cole et al. 2005; Li et al. 2000; Shih et
al. 1998). Other studies also indicate that the administration of purified plasma PON1
protein or, more recently, recombinant PON1 (Stevens et al. 2008), confers additional
resistance to chlorpyrifos and CPO (Li et al. 2000; Li et al. 1995; Costa et al. 1990). The
PON1 Q192R polymorphism significantly affects the catalytic efficiency of PON1 to
modulate the acute toxicity of OPs, which varies among compounds (Li et al. 2000;
Adkins et al. 1993; Davies et al. 1996; Humbert et al. 1993). For CPO, the PON1R192
alloform provided higher catalytic efficiency of hydrolysis than the PON1 Q192 alloform in
both in vitro and in vivo testing (Li et al. 2000). Studies using humanized transgenic mice
(i.e. mice with a deleted PON1 gene and human PON1 transgenes inserted that express
either the PON1Q192 or PON1R192 alleles) indicated that the mice expressing the PON1R192
allele were significantly less sensitive to the toxicity of CPO than the mice expressing the
PON1Q192 allele, even with the same level of PON1 protein in the liver and plasma (Cole
et al. 2005; Cole et al. 2003). Therefore, at high dose concentrations of CPO, both the
level of expression and the PON1192 genotype are important determinants of
susceptibility.
In the present study, the PON1192 genotype and the PON1 phenotype (i.e. activity
levels) were determined for African American and Caucasian male and female
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Southerners as described in Chapter 3. The PON1192 genotype was determined using a
restriction fragment length polymorphism assay and the PON1 phenotype was assessed
with two substrates, paraoxon and diazoxon. Forty subjects were chosen that were
designated as a PON1192QQ or PON1192RR genotype and that had either high or low
activities towards diazoxon and paraoxon. The hydrolysis of a high and a relatively low
concentration of CPO by PON1 was assessed using either a direct spectrophotometric
method or indirect method, respectively. Current research using humanized transgenic
mice use high doses of CPO to demonstrate that PON1192 genotype and level of activity
are significant determinants of susceptibility (Cole et al. 2005). However, studies fail to
demonstrate this principle in human serum at concentrations that are more relevant to
everyday exposure. The indirect method allows quantitation of hydrolysis of CPO at a
relatively low concentration that is closer to toxicologically relevant concentrations than
are the high concentrations assayed in traditional direct assay methods. The indirect assay
assesses the ability of residual CPO not hydrolyzed by PON1 to inhibit an exogenous
source of acetylcholinesterase. Acetylcholinesterase activity can be measured at levels
well below the detection limits of direct spectrophotometric methods and therefore, the
indirect method can measure CPO concentration levels that would be more reflective of
realistic exposure scenarios.
Materials and methods
Study Population
Subjects were enrolled in the study from the clinical practice of Cardiology
Associates of North Mississippi, LLC, a cardiology group located in Tupelo, Mississippi,
which draws the vast majority of its patients from the 26 counties comprising northeast
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Mississippi and northwest Alabama. The research division of this clinic, Cardiology
Associates Research, LLC (CARe), collected a total of 200 serum samples from
Caucasians (60 male, 60 female) and African Americans (40 male, 40 female), ages 45
and older. A 60/40 split was chosen to reflect the racial composition of Mississippi.
After obtaining written informed consent, blood samples were collected when
vascular access was established for clinical testing. Serum was isolated by allowing blood
to clot, then centrifuging at 2500-3000 x g at 4°C for 10 to 20 minutes. The serum was
frozen on dry ice and stored at -70°C until analysis of PON1 activity. An aliquot of whole
blood anti-coagulated with K2EDTA was stored at -70°C for PON1 genotypic analysis.
The study protocol was approved by both the Institutional Review Board of
Mississippi State University and the IRB of North Mississippi Medical Center; the latter
provides oversight for studies performed at CARe.
PON1 phenotype of a subject was determined using diazoxon and paraoxon as
substrates (see paraoxonase and diazoxonase assay in methods) (Figure 3a). A subject‟s
PON1 phenotype was designated as “high” if he/she had high enzyme activity towards
diazoxon or paraoxon or designated as “low” if he/she had low enzyme activity towards
diazoxon or paraoxon (Figure 3c).
The PON1192 genotype for each individual was determined using a restriction
fragment length polymorphism assay (see PON1 genotyping in methods) (Figure 3a).
Subjects used in this study were determined to have either the PON1 Q192 alloform or the
PON1R192 alloform (Figure 3b). Subjects that were determined to be heterozygous (i.e.
QR192) were not used in this study (Figure 3b).
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Chemicals and samples
Paraoxon and chlorpyrifos-oxon were synthesized by Dr. Howard Chambers
(Department of Biochemistry, Molecular Biology, Entomology and Plant Pathology,
Mississippi State University. Diazoxon was purchased from ChemService (West Chester,
PA). All other chemicals were purchased from Sigma Chemical Company (St. Louis,
MO).
Paraoxonase and Diazoxonase Assays
Paraoxonase activity was determined by the hydrolysis of paraoxon as described
in detail by (Richter and Furlong 1999)with minor modifications (Davis et al. 2009).
Diazoxonase activity was determined by the hydrolysis of diazoxon as described in detail
by (Richter and Furlong 1999) with minor modifications (Davis et al. 2009). The
paraoxonase and diazoxonase assays were conducted in the presence of 2 M NaCl.
Samples were run in triplicate. Data were expressed as micromoles of paraoxon
hydrolyzed per minute per liter of serum for the paraoxonase assay and micromoles of
diazoxon hydrolyzed per minute per liter of serum for the diazoxonase assay.
Direct A-esterase assay for activity for chlorpyrifos-oxon activity
The direct assay of chlorpyrifos-oxonase activity was determined by the
hydrolysis of chlorpyrifos-oxon by PON1 as described in detail by Furlong et al. (1989)
with minor modifications by Pond et al. (1998).
A 5 µl aliquot of human serum was added to each tube in a set of 4 tubes in which
1 tube contained 1 ml EDTA buffer [Tris-HCl (0.1 M, pH 8.0), 1.0 mM EDTA] to inhibit
PON1 activity and the remaining 3 tubes containing 1 ml calcium buffer [Tris-HCl (0.1
M, pH 8.0), 2.0 mM CaCl2] to stimulate PON1 activity. A 10 µl aliquot of stock 32 mM
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CPO in ethanol was added to each tube (320 µM final concentration), and the tubes were
vortexed and incubated in a shaking water bath at 37ºC for 15 min. After incubation, 500
µl of 2% sodium dodecyl sulfate (SDS) was added to each tube. The solution was
vortexed and immediately transferred into a 1.5 ml disposable cuvette. The liberation of
3,5,6-trichloropyridinol (TCP) by chlorpyrifos-oxon hydrolysis was calculated using a
molar extinction coefficient of 7.704 x 103 M-1 cm-1. Absorbances were read at 315 nm
using the Thermo Biomate 3 spectrophotometer. Samples were analyzed in triplicate and
the values averaged. Data were expressed as micromoles of chlorpyrifos-oxon
hydrolyzed per minute per liter of serum.
Calculation of Data
The change in absorbance units (ΔAU) was calculated from the difference
between the Ca2+-fortified sample (AUCa2+) and the EDTA-containing sample (AUEDTA)
for each tube:
ΔAU = (AVG AUCa2+) - (AVG AUEDTA)

Equation 1

Micromoles of chlorpyrifos-oxon hydrolyzed per min per liter of serum was
calculated using a molar extinction coefficient of 7.704 x 10 3 M-1 cm-1 from Pond et al.
(1998):
Activity = ∆ AU x 7.704 x 103 µmol
(AU)(L)(min)

Equation 2

Here:
7.704 x 103 µmol = conversion factor
(AU)(L)(min)

Equation 3

Indirect A-esterase assay for activity for chlorpyrifos-oxon activity
A 10 µl aliquot of human serum was added to 4 sets of 4 tubes in which 2 tubes
contained 1 ml EDTA buffer [Tris-HCl (0.1 M, pH 8.0), 1.0 mM EDTA] to inhibit PON1
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activity and 2 tubes containing 1 ml calcium buffer [Tris-HCl (0.1 M, pH 8.0), 2.0 mM
CaCl2] to stimulate PON1 activity. A 10 µl aliquot of iso-OMPA
(tetraisopropylpyrophosphoramide; 0.01 mM stock concentration in ethanol), to inhibit
serum butyrylcholinesterase activity, was added to each tube (0.0001 mM final
concentration), and all the tubes were vortexed and incubated in a shaker bath at 37ºC for
5 min. After the incubation, 10 µl of ethanol, to serve as a control, or chlorpyrifos-oxon
(178 nM in ethanol final concentration) was added to 2 tubes of each set, and all the tubes
were vortexed and incubated in a shaker bath at 37ºC for 15 min. The 178 nM CPO
concentration was determined from a log-logit standard concentration curve that
produced ~90% electric eel acetylcholinesterase (AChE) inhibition with EDTA buffer
and ~20% electric eel AChE inhibition with calcium buffer. After the incubation, 1 ml of
0.15 unit/ml electric eel AChE was added to each tube (0.075 unit/ml final
concentration), vortexed, and incubated in a shaker bath at 37ºC for 15 min. Eight mls of
Tris-HCl buffer (0.05 M, pH 7.7, 25ºC) was added to sixteen 15-ml centrifuge tubes.
After incubation, the entire reaction m A 10 µl aliquot of human serum was added to 4
sets of 4 tubes in which 2 tubes contained 1 ml EDTA buffer [Tris-HCl (0.1 M, pH 8.0),
1.0 mM EDTA] to inhibit PON1 activity and 2 tubes containing 1 ml calcium buffer
[Tris-HCl (0.1 M, pH 8.0), 2.0 mM CaCl2] to stimulate PON1 activity. A 10 µl aliquot of
iso-OMPA (tetraisopropylpyrophosphoramide; 0.01 mM stock concentration in ethanol),
to inhibit serum butyrylcholinesterase activity, was added to each tube (0.0001 mM final
concentration), and all the tubes were vortexed and incubated in a shaker bath at 37ºC for
5 min. After the incubation, 10 µl of ethanol, to serve as a control, or chlorpyrifos-oxon
(178 nM in ethanol final concentration) was added to 2 tubes of each set, and all the tubes
were vortexed and incubated in a shaker bath at 37ºC for 15 min. The 178 nM CPO
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concentration was determined from a log-logit standard concentration curve that
produced ~90% electric eel acetylcholinesterase (AChE) inhibition with EDTA buffer
and ~20% electric eel AChE inhibition with calcium buffer. After the incubation, 1 ml of
0.15 unit/ml electric eel AChE was added to each tube (0.075 unit/ml final
concentration), vortexed, and incubated in a shaker bath at 37ºC for 15 min. Eight mls of
Tris-HCl buffer (0.05 M, pH 7.7, 25ºC) was added to sixteen 15-ml centrifuge tubes.
After incubation, the entire reaction mixture of 1 tube was transferred into one of the
sixteen 15-ml centrifuge tubes and vortexed. ixture of 1 tube was transferred into one of
the sixteen 15-ml centrifuge tubes and vortexed.
Acetylcholinesterase Assay
Each of the sixteen 15-ml centrifuge tubes were aliquoted into 2 ml assay volume
(0.015 unit/ml electric eel AChE final concentration) into 16 sets of 4 tubes (one 15-ml
centrifuge tube per set). To inhibit electric eel AChE activity, 20 µl of eserine sulfate (1.0
mM stock concentration in 0.05 M Tris-HCl buffer) was added to the first tube of each
set (0.01 mM final concentration) and vortexed. These tubes were designated as blanks.
All 16 sets of 4 tubes were then incubated in a shaker bath at 37ºC for 15 min. After
incubation, 20 µl of acetylthiocholine (ATCh; 100 mM stock concentration in ethanol)
was added to all tubes (1 mM final concentration), vortexed, and incubated in a shaker
bath at 37ºC for an additional 15 min. In a 50-ml beaker, 20 mls of 5% SDS (sodium
dodecyl sulfate) and 5 mls of 2.6 mM DTNB [5,5'-dithio-bis (2-nitrobenzoic acid)] were
added together to form a 5% SDS/DTNB mixture. After the incubation, 250 µl of the 5%
SDS/DTNB mixture were added to all tubes. The solutions were vortexed and
immediately transferred into a 1.5 ml disposable cuvettes. The electric eel AChE activity
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was measured using a Thermo Biomate 3 spectrophotometer at 412 nm. Samples were
analyzed in triplicate and the values averaged. Data were expressed in nanomoles CPO
hydrolyzed per min per liter of serum.
Calculation of Data
The indirect method monitored the inhibition of electric eel AChE to quantify the
residual oxon not hydrolyzed by PON1. The percent inhibition (%I) for EDTA and
calcium assay tubes were converted to logits by taking the log of [(%I) ÷ (100-%I)] for
both EDTA and calcium. A log-logit standard curve plot for chlorpyrifos-oxon inhibition
of electric eel AChE vs. CPO concentration was then used to determine the nanomolar
concentration of CPO not hydrolyzed by PON1. The concentration of CPO which
produced about 20% electric eel AChE inhibition with calcium was subtracted from the
concentration of CPO which produced about 90% electric eel AChE inhibition with
EDTA (reflecting non-PON-mediated hydrolysis of CPO). Data were expressed in
nanomoles CPO hydrolyzed per minute per liter of serum.
PON1 Genotyping
Genomic DNA was isolated from whole blood using a Sigma-Aldrich®
GenEluteTM Blood Genomic DNA Kit and concentrated using a Qiagen QIAEX®II Gel
Extraction Kit. Following the method received from the Medical Genetics Department of
the University of Washington (Jane Ranchalis, personal communication), a region
containing the PON1192 codon was amplified by PCR to yield a 99 bp product using the
primer pair F 5' TATTGTTGCTGTGGGACCTGAG 3' and R 5'
TGAAAGACTTAAACT 3'. Each PCR reaction contained ~200 ng of purified human
DNA at ~100 ng/µl, 2 µl of 10X AmpliTaq Gold® 360 PCR Buffer (ABI), 2 µl of 25
43

mM MgCl2, 0.16 µl 25 mM dNTPs (Promega), 0.2 µl of each primer at 25 µM, 0.2 µl
AmpliTaq Gold polymerase (ABI) at 5U/µl, 1 µl of dimethylsulfoxide and water
sufficient to bring the final volume to 20 µl. Since there is a native Alw I restriction site
at codon 192, 10 µl of the PCR product solution was digested with Alw I (NEB)
overnight and visualized by ethidium bromide staining on a 3% agarose gel next to 10 µl
of undigested product solution. The digestion resulted in 63- and 36-bp fragments for
individuals with the PON1192RR genotype; 99-, 63-, and 36-bp fragments for individuals
with the PON1192QR genotype; and a single, non-digested 99-bp fragment for individuals
with the PON1192QQ genotype. Sequence data confirmed the results from the restriction
digest analyses for all 50 of the 200 participants sequenced.
Statistical Analysis
A two way analysis of variance using PROC GLM (SAS for Windows 9.1.3, SAS
Institute Inc., Cary, NC, USA) was used to determine if there were statistically significant
differences among PON1192 genotypes, PON1 phenotypes, and PON1192 genotype-PON1
phenotype interactions. If interaction term was found to be significant, mean separation
tests were conducted using Tukey adjustment of the least square means. All statistical
comparisons used a p-value ≤0.05 to demonstrate statistical significance.
Results
PON1 Genotypes
Separation of the 200 individuals of this study into the three functional PON1192
genotypes through the 2-dimensional plot of diazoxonase vs. paraoxonase in the presence
of 2 M NaCl was not as clear as previously reported (Richter and Furlong 1999; Davis et
al. 2009). In fact, the diazoxonase vs. paraoxonase in the presence of 2 M NaCl plot alone
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was unable to unambiguously assign a functional genotype to a number of individuals.
Therefore, the PON1192 genotype was determined using a restriction fragment length
polymorphism assay. Assignment of genotypes to the data points on the diazoxonase vs.
paraoxonase in the presence of 2 M NaCl plot showed that individuals with each of the
three PON1192 genotypes were located in the expected region of the plot (Figure 3a).
Chlorpyrifos-oxon Hydrolysis using Direct Assay
Statistically significant differences (p≤ 0.05) between PON1192 genotypes, PON1
phenotypes, PON1192 genotype-PON1 phenotype interactions were determined by twoway ANOVA. Subjects who expressed the PON1R192 alloform hydrolyzed significantly
more CPO than subjects who expressed the PON1Q192 alloform (p< 0.0001). Subjects
who expressed the PON1Q192 alloform and had a high activity phenotype (i.e. high QQ)
hydrolyzed significantly more CPO than subjects who expressed the PON1 Q192 alloform
and had a low activity phenotype (i.e. low QQ) (p< 0.0001) (Table 5). Similarly, subjects
who expressed the PON1R192 alloform and had a high activity phenotype (i.e. high RR)
hydrolyzed significantly more CPO than subjects who expressed the PON1 R192 alloform
and had a low activity phenotype (i.e. low RR) (p= 0.0002) (Table 5).
Subjects who expressed the PON1R192 alloform with a high activity phenotype
hydrolyzed significantly more CPO than subjects who expressed the PON1 Q192 alloform
with a high activity phenotype (p< 0.0001) (Table 5). Additionally, subjects who
expressed the PON1R192 alloform with a low activity phenotype hydrolyzed significantly
more CPO than subjects who expressed the PON1Q192 alloform with a low activity
phenotype (p< 0.0001) (Table 5).
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Chlorpyrifos-oxon Hydrolysis using Indirect Assay
No significant associations (p≤ 0.05) between PON1192 genotype, PON1
phenotype, PON1192 genotype-PON1 phenotype interactions were determined by twoway ANOVA. There were no significant differences in the hydrolysis of CPO between
subjects who expressed the PON1R192 or PON1Q192 alloforms (p= 0.0749). There were no
significant differences in the hydrolysis of CPO between subjects who expressed the
PON1Q192 alloform with a high or a low activity phenotype (p= 0.7416) (Table 2).
Similarly, there were no significant differences in the hydrolysis of CPO between
subjects who expressed the PON1R192 alloform with a high or a low activity phenotype
(p= 0.5278) (Table 6).
Subjects who expressed the PON1R192 alloform with a high activity phenotype did
not hydrolyze CPO more efficiently than subjects who expressed the PON1 Q192 alloform
with a high activity phenotype (p= 0.0769) (Table 6). Additionally, subjects who
expressed the PON1R192 alloform with a low activity phenotype did not hydrolyze CPO
more efficiently than subjects who expressed the PON1 Q192 alloform with a low activity
phenotype (p= 0.1237) (Table 6).
Discussion
Plasma PON1 phenotypes are highly variable among human populations with
individuals exhibiting high, intermediate, or low paraoxonase activity (Diepgen and
Geldmacher-von Mallinckrodt 1986; Eckerson et al. 1983; Mueller et al. 1983). The
coding region polymorphisms of PON1 have also been investigated for effects of
catalytic efficiencies of certain OPs. Studies have elucidated that the PON1 Q192R
polymorphism significantly affects the catalytic efficiency of PON1 but is substrate
dependent (Li et al. 2000; Adkins et al. 1993; Davies et al. 1996; Humbert et al. 1993).
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In this study, PON1 hydrolysis of CPO at a relatively high concentration (320
µM) measured by direct assay using human serum concur with previous reports that both
serum PON1 phenotype and PON1192 genotype are important determinants of CPO
sensitivity at a high dose in vivo in transgenic animal models (Cole et al. 2005; Li et al.
2000; Shih et al. 1998). Our data indicate that differences in serum PON1 phenotypes are
important for predicting sensitivity towards CPO at high concentrations with subjects
having high PON1 phenotypes hydrolyzing significantly more CPO than subjects with
low PON1 phenotypes. Additionally, subjects who expressed the PON1 R192 alloform
hydrolyzed significantly more CPO than subjects expressing the PON1 Q192 alloform at
the high CPO concentration.
However, PON1 hydrolysis of CPO at a relatively low concentration (178 nM)
measured by our indirect method using human serum contradicted studies using direct
methods of measurement and high concentrations of CPO (Cole et al. 2005; Li et al.
2000; Shih et al. 1998; Jansen et al. 2009). At a low CPO concentration that is closer to a
toxicologically relevant concentration, the data indicated that neither serum PON1
phenotypes nor PON1192 genotype influence PON1‟s ability to hydrolyze CPO. This is
likely due to the amount of CPO present in the assay not being able to saturate the PON1
enzyme, and therefore PON1 was not functioning at maximal velocity (Cole et al. 2005;
Li et al. 2000; Li et al. 1995; Jansen et al. 2009).
Conclusion
This is the first study to demonstrate hydrolysis of CPO by PON1 at a low and
more toxicologically relevant concentration (178 nM) in human serum. Similar to
humanized mouse models, significant differences were shown between the PON1192
47

genotypes and between high and low serum PON1 phenotypes with the PON1R192
alloform hydrolyzing significantly more CPO than the PON1 Q192 alloform at a relatively
high concentration (320 µM). However, no significant differences were demonstrated
between the PON1192 genotypes and between high and low serum PON1 phenotypes at a
low CPO concentration (178 nM). Therefore, at a low concentration more reflective of
levels that would occur under realistic exposure scenarios, neither PON1192 genotype nor
serum PON1 phenotypes influences the capacity of PON1 to metabolize CPO
presumably because PON1 is not saturated at these low CPO concentrations.
Table 5

Direct assay measurement of chlorpyrifos-oxon hydrolysis

High RR
11023 ± 722A

Low RR
9467 ± 798B

High QQ
8809 ± 672B

Low QQ
6030 ± 1015C

a

Activities are expressed as micromoles of chlorpyrifos-oxon hydrolyzed
per minute per L of serum, means ± SD
A
Values with the same superscript letter are not significantly different (p≤ 0.05) as
determined by analysis of variance with Tukey adjustment
Table 6

Indirect assay measurement of chlorpyrifos-oxon hydrolysis

High RR
231 ± 27A

Low RR
219 ± 52A

High QQ
193 ± 59A

a

Low QQ
185 ± 43A

Activities are expressed as nanomoles of chlorpyrifos-oxon hydrolyzed per
minute per L of serum, means ± SD
A
Values with the same superscript letter are not significantly different (p≤ 0.05) as
determined by analysis of variance with Tukey adjustment
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Figure 3

Plot of serum DZOaseNa vs. POaseNa enzymatic activities.

The sample population (n=200) consisted of 120 Caucasians (60 male, 60 female) and 80
African Americans (40 male, 40 female). (A) Plot of diazoxonase activities vs.
paraoxonase activities in 2 M NaCl in the sera of male and female African American and
Caucasian Southerners with the PON1192QQ (○); PON1192QR (■); PON1192RR (∆)
genotypes for each individual. (B) Plot of diazoxonase activities vs. paraoxonase
activities in 2 M NaCl in the sera of male and female African American and Caucasian
Southerners with the PON1192QQ (○) and PON1192RR (∆) genotypes only. (C) Plot of
diazoxonase activities vs. paraoxonase activities in 2 M NaCl in the sera of male and
female African American and Caucasian Southerners with the PON1 192QQ (○) and
PON1192RR (∆) genotypes used in this study.
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CHAPTER V
CONCLUSIONS
Overwhelming health disparities occur in the southeastern United States,
specifically Mississippi, and among those prominent health disparities is the prevalence
of cardiovascular disease. Within these Southern states the occurrence of cardiovascular
disease is more prevalent in the African American population than in the Caucasian
population. Epidemiological studies concerned with cardiovascular disease have not
focused on southern populations, nor have African Americans been an important
proportion of these studies where cardiovascular health is the worst.
This study is one of the first to report the frequency distribution of the PON1192
genotypes (QQ, QR, RR) in African American and Caucasian Southerners and the
possible differences between PON1192 enzymatic activities (diazoxonase, paraoxonase
and phenylacetate) within race, gender, age and presence of atherosclerotic disease.
PON1 genotyping documented that the African American population displayed a greater
proportion of the PON1192RR genotype than did Caucasians, while the reverse was true
with the PON1192QQ genotype. In addition, this study developed a model that documented
a protective effect of serum PON1 enzyme activity, as assessed by the hydrolysis of
phenylacetate, on atherosclerosis occurrence while accounting for age, gender, history of
smoking, hypertension and elevated low density lipoprotein cholesterol levels.
This study is also the first to document the hydrolysis of chlorpyrifos-oxon by
PON1 at a low more toxicologically relevant concentration (178 nM) in the sera of the
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study population using an indirect spectrophotometric method. The indirect method
reported that neither PON1192 genotype nor serum PON1192 activity levels had a
significant effect on the hydrolysis of chlorpyrifos-oxon by PON1 at a low concentration
(178 nM) which is more reflective of levels that would occur under realistic exposure
scenarios.
These data suggest that a greater subject population of African American and
Caucasian Southerners are warranted where cardiovascular health status, demographic
and clinical information are known. This study focused on the PON1 Q192R
polymorphism and correlations with atherosclerosis; however, other polymorphisms
which may demonstrate different sensitivity to organophosphate toxicity or correlations
with atherosclerosis were not observed. Additionally, the subject population, whether
participating in farming or not, were likely exposed to agricultural chemicals including
pesticides since the area is rural and highly agricultural. Our lab is currently engaged in
determining the PON1 L55M polymorphism of the subject population and determining
any associations to atherosclerosis. In addition, our lab is determining organochlorine
pesticide levels in the sera of the subject population and determining any association with
the PON1 Q192R polymorphism and atherosclerosis.
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